ORPHAN SYNERGY EUROPE-PHARMA (EPA:OSE) | WebDisclosure

Basculer en Français

10822	Companies
234741	Keywords
163577	Articles
125616	Press releases

Headlines Articles Press releases ORPHAN SYNERGY EUROPE-PHARMA

Home
Companies
ORPHAN SYNERGY EUROPE-PHARMA

PRESS RELEASE

published on 06/03/2026 at 20:19, 2 months 8 days ago

OSE Immunotherapeutics publie ses résultats financiers consolidés audités pour l’exercice 2025 et annonce le dépôt de son Document d’Enregistrement Universel 2025
OSE Immunotherapeutics publie ses résultats financiers consolidés audités pour l’exercice 2025 et annonce le dépôt de son Document d’Enregistrement Universel 2025

Résultats Financiers Trésorerie Document D’enregistrement Universel OSE Immunotherapeutics Audités
PRESS RELEASE

published on 06/03/2026 at 20:19, 2 months 8 days ago

OSE Immunotherapeutics Reports Full Year 2025 Audited Consolidated Financial Results and Announces the Filing of its 2025 Universal Registration Document
OSE Immunotherapeutics reports full year 2025 audited consolidated financial results and filing of 2025 Universal Registration Document, confirming cash runway with IRIS Financing

Universal Registration Document OSE Immunotherapeutics Cash Runway 2025 Financial Results IRIS Financing
BRIEF

published on 05/28/2026 at 21:09, 2 months 14 days ago

OSE Immunotherapeutics obtient un financement relais flexible en fonds propres

Plan Stratégique Investisseurs Institutionnels Développement Clinique Émission D'actions Financement Flexible
BRIEF

published on 05/28/2026 at 21:09, 2 months 14 days ago

OSE Immunotherapeutics Secures Flexible Bridge Equity Financing

Strategic Plan Clinical Development Institutional Investors Share Issuance Flexible Financing
PRESS RELEASE

published on 05/28/2026 at 21:04, 2 months 14 days ago

OSE Immunotherapeutics met en place un financement relais flexible en fonds propres
OSE Immunotherapeutics lance un financement relais flexible en fonds propres avec IRIS Capital Investment pour un montant pouvant atteindre 19,3 millions d'euros sur 24 mois, prolongeant ainsi son horizon de trésorerie jusqu'à fin décembre 2026

Financement Fonds Propres OSE Immunotherapeutics Horizon De Trésorerie IRIS Capital Investment
PRESS RELEASE

published on 05/28/2026 at 21:04, 2 months 14 days ago

OSE Immunotherapeutics to Implement a Flexible Bridge Equity Financing
OSE Immunotherapeutics announces a flexible bridge equity financing with IRIS Capital Investment to raise €19.3 million, extending cash runway to December 2026 as part of a global financing strategy

OSE Immunotherapeutics Cash Runway Extension Bridge Equity Financing IRIS Capital Investment Global Financing Strategy
BRIEF

published on 05/22/2026 at 07:35, 2 months 21 days ago

OSE Immunotherapeutics Announces Positive Results in Ovarian Cancer Trial

Ovarian Cancer Clinical Trial Results OSE Immunotherapeutics Tedopi® TEDOVA Phase 2
BRIEF

published on 05/22/2026 at 07:35, 2 months 21 days ago

OSE Immunotherapeutics annonce des résultats positifs dans un essai clinique sur le cancer de l'ovaire

Résultats Des Essais Cliniques Tedopi® Immunothérapies OSE Cancer De L'ovaire Phase 2 De TEDOVA
PRESS RELEASE

published on 05/22/2026 at 07:30, 2 months 21 days ago

OSE Immunotherapeutics Reports Positive Topline Results of TEDOVA Phase 2 Trial with Tedopi® in Recurrent Ovarian Cancer
OSE Immunotherapeutics announces positive topline results from TEDOVA Phase 2 trial with Tedopi® in recurrent ovarian cancer, presenting at ASCO 2026. Combination with pembrolizumab improves progression-free survival

OSE Immunotherapeutics Tedopi TEDOVA Phase 2 ASCO 2026 Recurrent Ovarian Cancer
BRIEF

published on 04/30/2026 at 07:35, 3 months 12 days ago

OSE Immunotherapeutics: 2025 Financial Review and 2026 Outlook

Strategic Partnerships OSE Immunotherapeutics 2025 Financial Results Tedopi® Cash Flow 2026

Accesswire

Published on 08/12/2026 at 09:01, 1 hour ago

Apex Drills 4.48% REO Over 8.0 m and 5.27% REO Over 10.2 m Within Multiple ~ 150 m Intervals of > 2.00 % REO at the Rift Rare Earth Project in SE Nebraska
Published on 08/12/2026 at 08:02, 1 hour 59 minutes ago

Southern Energy Corp. Announces Spudding of Cotton Valley Test Well at Williamsburg and Appointment of Market Maker
Published on 08/12/2026 at 08:00, 2 hours 1 minute ago

Galantas Selects Engineering and Mine Planning Contractors for Andacollo Gold Project
Published on 08/12/2026 at 00:00, 10 hours 1 minute ago

Organto Foods Reports Record Second Quarter 2026 Financial Results
Published on 08/11/2026 at 23:40, 10 hours 21 minutes ago

RJK Explorations Ltd. Announces Private Placement for Gross Proceeds of up to $100,000

View all ACCESSWIRE

EQS Group

Published on 08/12/2026 at 09:05, 56 minutes ago

BASF Agricultural Solutions invests in new Climate Center at its headquarters to strengthen research capabilities
Published on 08/12/2026 at 09:05, 56 minutes ago

Partnership between Novem and GPAINNOVA for the implementation of DLyte® technology
Published on 08/12/2026 at 09:00, 1 hour 1 minute ago

Original-Research: LAIQON AG (von NuWays AG): BUY
Published on 08/12/2026 at 09:00, 1 hour 1 minute ago

Original-Research: Multitude AG (von NuWays AG): BUY
Published on 08/12/2026 at 09:00, 1 hour 1 minute ago

Official List Notice

Les Echos

Published on 08/11/2026 at 17:45, 16 hours 16 minutes ago

DAMARTEX / Droits de vote bruts et réels au 31 juillet 2026
Published on 08/11/2026 at 17:40, 16 hours 21 minutes ago

Infotel : Déclaration des transactions sur actions propres réalisées du 3 au 7 août 2026 dans le cadre du programme de rachat d’actions
Published on 08/10/2026 at 18:00, 1 day 16 hours ago

AXA: Information relating to the number of voting rights and shares making up the share capital on 31/07/2026
Published on 08/10/2026 at 18:00, 1 day 16 hours ago

AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 31/07/2026
Published on 08/10/2026 at 17:45, 1 day 16 hours ago

Weekly share buyback

View all LES ECHOS COMFI WIRE